$903 Million is the total value of SECTORAL ASSET MANAGEMENT INC's 55 reported holdings in Q4 2016. The portfolio turnover from Q3 2016 to Q4 2016 was 40.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CELG | Sell | CELGENE CORP | $50,233,000 | -0.3% | 433,981 | -10.0% | 5.56% | +12.5% |
| NBIX | Sell | NEUROCRINE BIOSCIENCES | $28,986,000 | -28.7% | 748,988 | -6.7% | 3.21% | -19.6% |
| CI | Sell | CIGNA CORP | $28,335,000 | +1.1% | 212,424 | -1.2% | 3.14% | +14.1% |
| ABMD | Sell | ABIOMED INC | $28,330,000 | -13.2% | 251,416 | -0.9% | 3.14% | -2.0% |
| SHPG | Sell | SHIRE PLCsp adr | $26,947,000 | -16.3% | 158,158 | -4.8% | 2.98% | -5.6% |
| NXTM | Sell | NXSTAGE MEDICAL | $23,361,000 | -22.1% | 891,313 | -25.7% | 2.59% | -12.1% |
| WMGI | Sell | WRIGHT MED GROUP N V | $10,547,000 | -14.9% | 458,977 | -9.1% | 1.17% | -3.9% |
| AERI | Sell | AERIE PHARMACEUTICALS | $8,906,000 | -5.3% | 235,298 | -5.6% | 0.99% | +6.9% |
| XLRN | Sell | ACCELERON PHARMA | $8,810,000 | -49.5% | 345,225 | -28.3% | 0.98% | -43.0% |
| NVO | Sell | NOVO-NORDISK ASadr | $8,477,000 | -54.2% | 236,380 | -46.9% | 0.94% | -48.3% |
| MOH | Sell | MOLINA HEALTHCARE | $7,425,000 | -16.9% | 136,845 | -10.6% | 0.82% | -6.2% |
| PRTA | Sell | PROTHENA CORP PLC | $6,082,000 | -18.2% | 123,646 | -0.2% | 0.67% | -7.7% |
| INCY | Sell | INCYTE CORPORATION | $3,447,000 | -83.7% | 34,374 | -84.6% | 0.38% | -81.5% |
| ENTL | Sell | ENTELLUS MED INC | $2,476,000 | -16.4% | 130,496 | -2.3% | 0.27% | -5.8% |
| PTCT | Sell | PTC THERAPEUTICS I | $1,343,000 | -87.7% | 123,135 | -84.2% | 0.15% | -86.1% |
| DBVT | Sell | DBV TECHNOLOGIESsp adr | $1,349,000 | -5.5% | 38,401 | -2.3% | 0.15% | +6.4% |
| AVXS | Sell | AVEXIS INC | $1,108,000 | -81.6% | 23,215 | -84.2% | 0.12% | -79.3% |
| ALNY | Sell | ALNYLAM PHARMACEUTICALS | $745,000 | -57.4% | 19,899 | -22.9% | 0.08% | -51.7% |
| DNAI | Exit | PRONAI THERAPEUTICS | $0 | – | -201,660 | -100.0% | -0.04% | – |
| NTLA | Exit | INTELLIA THERAPEUTICS | $0 | – | -123,159 | -100.0% | -0.23% | – |
| LCI | Exit | LANNETT CO INC | $0 | – | -87,693 | -100.0% | -0.23% | – |
| RGNX | Exit | REGENXBIO INC | $0 | – | -243,613 | -100.0% | -0.32% | – |
| TMH | Exit | TEAM HEALTH HOLDINGS | $0 | – | -185,560 | -100.0% | -0.59% | – |
| AMSG | Exit | AMSURG CORP | $0 | – | -96,560 | -100.0% | -0.64% | – |
| OPHT | Exit | OPHTHOTECH CORP | $0 | – | -389,363 | -100.0% | -1.76% | – |
| VRTX | Exit | VERTEX PHARMACEUTICALS | $0 | – | -217,874 | -100.0% | -1.86% | – |
| TEVA | Exit | TEVA PHARMACEUTICALadr | $0 | – | -454,172 | -100.0% | -2.05% | – |
| ALGN | Exit | ALIGN TECH INC | $0 | – | -242,641 | -100.0% | -2.23% | – |
| GILD | Exit | GILEAD SCIENCES INC | $0 | – | -524,165 | -100.0% | -4.07% | – |
| MDT | Exit | MEDTRONIC PLC | $0 | – | -521,241 | -100.0% | -4.42% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-02-10
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| BIOMARIN PHARMAC INC | 45 | Q2 2024 | 6.7% |
| DR REDDYS LABS LTD | 45 | Q2 2024 | 2.0% |
| PTC THERAPEUTICS INC | 43 | Q2 2024 | 2.7% |
| GILEAD SCIENCES INC | 41 | Q2 2024 | 8.4% |
| VERTEX PHARMACEUTICL | 41 | Q2 2024 | 6.0% |
| INCYTE CORPORATION | 41 | Q2 2024 | 5.2% |
| AMICUS THERAPEUTICS INC | 40 | Q2 2024 | 6.6% |
| PFIZER INC | 38 | Q2 2024 | 6.3% |
| MERCK & CO. INC | 37 | Q2 2024 | 6.4% |
| MEDTRONIC PLC | 36 | Q2 2024 | 4.4% |
View SECTORAL ASSET MANAGEMENT INC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| eFFECTOR Therapeutics, Inc. | February 14, 2024 | 2,382,644 | 3.7% |
| Galera Therapeutics, Inc.Sold out | February 14, 2024 | 0 | 0.0% |
| Aprea Therapeutics, Inc. | February 12, 2021 | 163,681 | 0.8% |
| LA JOLLA PHARMACEUTICAL CO | February 13, 2020 | ? | ? |
| COLLEGIUM PHARMACEUTICAL, INC | February 13, 2018 | 1,426,862 | 4.4% |
| Advaxis, Inc. | February 10, 2017 | 690,074 | 1.7% |
| AMICUS THERAPEUTICS INC | February 10, 2017 | 5,100,198 | 3.6% |
| OncoMed Pharmaceuticals Inc | February 12, 2016 | ? | ? |
| IRONWOOD PHARMACEUTICALS INC | February 13, 2015 | ? | ? |
| SEQUENOM INC | February 12, 2014 | ? | ? |
View SECTORAL ASSET MANAGEMENT INC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-08-13 |
| N-PX | 2024-08-09 |
| 13F-HR | 2024-05-14 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-12 |
| SC 13G/A | 2023-02-13 |
View SECTORAL ASSET MANAGEMENT INC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.